Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

BACKGROUND AND OBJECTIVE: Sintilimab has superior efficacy and safety in patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost-effectiveness in China is unclear. This study is to evaluate the cost-effectiveness of sintilimab plus chemotherapy vs. pembrolizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Pingyu, Wang, Xintian, Zhu, Shengwen, Li, Hongchao, Rui, Mingjun, Wang, Yingcheng, Sun, Haikui, Ma, Aixia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395965/
https://www.ncbi.nlm.nih.gov/pubmed/36016894
http://dx.doi.org/10.3389/fpubh.2022.956792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395965/
https://www.ncbi.nlm.nih.gov/pubmed/36016894
http://dx.doi.org/10.3389/fpubh.2022.956792

Ejemplares similares